AWS Launches AI Platform That Designs 300,000 Antibody Molecules and Slashes Drug Discovery Timeline From a Year to Weeks

AWS launches Amazon Bio Discovery, an AI-powered platform that designed nearly 300,000 novel antibody molecules in collaboration with Memorial Sloan Kettering Cancer Center, slashing drug discovery timelines from up to a year down to just weeks.

• AWS launches Amazon Bio Discovery, a new AI-powered application giving scientists direct access to specialized biological foundation models to accelerate drug discovery and antibody design.
• The platform features an AI agent that guides researchers through experiments using natural language, integrates with lab partners for physical testing, and creates a feedback loop where results continuously improve future designs.
• In a real-world test with Memorial Sloan Kettering Cancer Center, the application designs nearly 300,000 novel antibody molecules and reduces the candidate-to-lab-testing timeline from up to a year down to just weeks.